KR102561289B1 - Peptide for whitening and cosmetic composition with improved percutaneous absorption comprising the same - Google Patents

Abstract

A peptide having whitening activity and a liposome cosmetic composition for improving percutaneous absorption containing the same are disclosed. The peptide according to one embodiment exhibits excellent whitening activity compared to conventional peptides, and the cosmetic composition according to one embodiment exhibits excellent stability and percutaneous absorption improvement effect.

Description

Peptide for whitening and cosmetic composition containing the same with improved percutaneous absorption

The following examples relate to whitening peptides and cosmetic composition techniques with improved percutaneous absorption containing the same.

Skin, as the primary barrier of the human body, protects internal organs from external environmental stimuli such as temperature and humidity changes, ultraviolet rays, and pollutants, and plays an important role in maintaining body homeostasis such as regulating body temperature.

As the industry develops, environmental pollution becomes serious, and interest in anti-aging and whitening of the skin is increasing. In particular, human skin constantly undergoes changes, and the most representative change is a decrease in skin function and visual beauty due to aging. Phenomenon in the final skin appearance as a result of skin aging includes formation of wrinkles, decrease in skin elasticity, formation of senile spots, etc., and formation of wrinkles is considered the most representative phenomenon.

Lipids, proteins, polysaccharides, and nucleic acids, which are major constituents of the skin, are oxidized and skin cells and tissues may be destroyed, resulting in aging of the skin. In particular, the oxidation of proteins can cut connective tissues such as collagen, hyaluronic acid, elastin, proteoglycan, and fibronectin, etc., and cause excessive inflammatory reactions.

Therefore, it is desirable to protect cell membranes by scavenging active oxygen species generated during the metabolic process of the body or mediated by ultraviolet irradiation and inflammatory reactions, and to restore skin health by regenerating damaged cells through active metabolism.

On the other hand, melanin is converted from tyrosine to dopa and dopaquinone by the action of tyrosinase present in pigment cells and is produced through dopachrome and the like. Melanin plays a role in protecting the body from harmful factors such as ultraviolet rays and regulating the secretion of hormones in the body.

However, since melanin is overproduced, it can promote the formation of melasma and freckles and skin aging, and can be involved in the induction of skin cancer, so research and development for suppressing the overproduction of melanin is being actively conducted.

Conventionally, ascorbic acid (Japanese Patent Laid-open Hei 4-9320), hydroquinone (Japanese Patent Laid-Open No. 6-192062), kojic acid (Japanese Patent Laid-open Publication No. 56-7710), arbutin (Japanese Patent Laid-Open No. 4-93150), plant extracts, etc. have shown tyrosinase inhibitory activity and have been used as whitening cosmetics. However, these components have insufficient stability in cosmetic formulations, may be decomposed and colored, or may cause off-flavors, and their use is limited due to unclear safety or efficacy in vivo.

Meanwhile, the cosmetics industry is actively developing products using natural substances to reduce skin irritation caused by chemicals. However, cosmetic materials derived from natural products, despite their eco-friendly characteristics, are easily deteriorated in the cosmetic composition and functionality is not completely implemented, or research on natural materials at home and abroad is saturated, making it difficult to discover new materials.

Therefore, based on the latest skin science theory, a new skin improvement mechanism is identified, and cosmetic material development using it is being actively conducted.

The present invention has been made to solve the above problems, and an object of the present invention is to provide a novel peptide having excellent biostability and excellent skin whitening activity.

As one problem, the present application is intended to provide a peptide having excellent skin whitening activity. As another task, the present application intends to provide a liposome cosmetic composition containing the peptide and having high stability and improved percutaneous absorption.

As one aspect to solve the above problems, the present invention provides a cosmetic composition for whitening, comprising the peptide of SEQ ID NO: 1 as an active ingredient.

According to one embodiment, it may contain 0.5 to 5.0% by weight of the active ingredient.

The cosmetic composition may be a formulation in which liposomes are formed by mixing an oil phase containing the active ingredient, phospholipid, and ceramide with an aqueous phase containing oleic acid, amino acid, and adenosine. The amino acid may include histidine or lysine.

According to one embodiment, the aqueous phase may further include purified water and EDTA, and the oil phase may further include ethanol, glycerin, 1,3-butylene glycol, stearic acid, and dibutylhydroxytoluene.

According to one embodiment, the EDTA is 0.03 to 0.07 parts by weight, the oleic acid is 0.1 to 0.4 parts by weight, the amino acid is 0.8 to 1.2 parts by weight, the adenosine is 0.8 to 1.2 parts by weight, the ethanol is 8 to 12 parts by weight, the glycerin is 25 to 35 parts by weight, the 1,3-butylene glycol is 8 to 12 parts by weight , The active ingredient is 0.8 to 1.2 parts by weight, the phospholipid is 2.5 to 3.5 parts by weight, the ceramide is 0.8 to 1.2 parts by weight, the stearic acid is 0.2 to 0.4 parts by weight, the dibutylhydroxytoluene is 0.03 to 0.07 parts by weight.

An apparatus according to an embodiment may be combined with hardware and controlled by a computer program stored in a medium to execute any one of the methods described above.

The peptide according to the embodiment has excellent skin whitening activity. The prescription example, which is a liposomal cosmetic composition containing the peptide, shows high storage stability and improved percutaneous absorption.

Hereinafter, embodiments will be described in detail with reference to the accompanying drawings. However, since various changes can be made to the embodiments, the scope of the patent application is not limited or limited by these embodiments. It should be understood that all changes, equivalents or substitutes to the embodiments are included within the scope of rights.

Specific structural or functional descriptions of the embodiments are disclosed for illustrative purposes only, and may be modified and implemented in various forms. Therefore, the embodiments are not limited to the specific disclosed form, and the scope of the present specification includes changes, equivalents, or substitutes included in the technical spirit.

Although terms such as first or second may be used to describe various components, such terms should only be construed for the purpose of distinguishing one component from another. For example, a first element may be termed a second element, and similarly, a second element may be termed a first element.

It should be understood that when an element is referred to as being “connected” to another element, it may be directly connected or connected to the other element, but other elements may exist in the middle.

Terms used in the examples are used only for descriptive purposes and should not be construed as limiting. Singular expressions include plural expressions unless the context clearly dictates otherwise. In this specification, terms such as "comprise" or "having" are intended to specify that a feature, number, step, operation, component, part, or combination thereof described in the specification exists, but it should be understood that the presence or addition of one or more other features or numbers, steps, operations, components, parts, or combinations thereof is not excluded in advance.

Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by a person of ordinary skill in the art to which the embodiment belongs. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related art, and are not interpreted in an ideal or excessively formal meaning unless explicitly defined in the present application.

Advantages and features of the present invention, and methods of achieving them, will become clear with reference to the detailed description of the following embodiments taken in conjunction with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in a variety of different forms, and only these embodiments make the disclosure of the present invention complete, and those skilled in the art It is provided to completely inform the scope of the invention, and the present invention is only defined by the scope of the claims.

In the embodiments of the present invention, unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related art, and unless explicitly defined in the embodiments of the present invention, an ideal or excessively formal meaning. It is not to be interpreted.

The shapes, sizes, ratios, angles, numbers, etc. disclosed in the drawings for explaining the embodiments of the present invention are illustrative, so the present invention is not limited to the details shown. In addition, in describing the present invention, if it is determined that a detailed description of related known technologies may unnecessarily obscure the subject matter of the present invention, the detailed description will be omitted. When 'includes', 'has', 'consists of', etc. mentioned in this specification is used, other parts may be added unless 'only' is used. In the case where a component is expressed in the singular, the case including the plural is included unless otherwise explicitly stated.

In interpreting the components, even if there is no separate explicit description, it is interpreted as including the error range.

The size and thickness of each component shown in the drawings are shown for convenience of description, and the present invention is not necessarily limited to the size and thickness of the illustrated components.

Each feature of the various embodiments of the present invention can be partially or entirely combined or combined with each other, and as those skilled in the art can fully understand, various interlocking and driving are possible technically, and each embodiment can be implemented independently of each other. It may be possible to implement together in a related relationship.

The cosmetic composition according to the present application may be prepared in the form of a general emulsified formulation and a solubilized formulation. For example, cosmetic lotion, such as softening lotion or nourishing lotion; emulsions such as facial lotion and body lotion; creams such as nourishing creams, moisture creams, and eye creams; essence; cosmetic ointment; spray; gel; pack; sunscreen; makeup base; foundations such as liquid type, solid type or spray type; powder; makeup removers such as cleansing creams, cleansing lotions, and cleansing oils; Alternatively, it may be formulated as a cleanser such as a cleansing foam, soap, body wash, etc., but is not limited thereto. In addition, the skin external preparation may be formulated as an ointment, patch, gel, cream or spray, but is not limited thereto.

In addition to the essential components in each formulation, the cosmetic composition or external preparation may be appropriately mixed with other components within a range that does not impair the purpose of the present invention depending on the type of formulation or purpose of use.

The cosmetic composition or external preparation may include a conventionally acceptable carrier, and for example, oil, water, a surfactant, a moisturizer, a lower alcohol, a thickener, a chelating agent, a colorant, a preservative, a flavoring agent, and the like may be appropriately blended, but is not limited thereto.

The acceptable carrier may vary depending on the formulation. For example, when formulated into an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or a mixture thereof may be used as a carrier component.

When the cosmetic composition or external agent is formulated as a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as a carrier component, and in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane, butane or dimethyl ether may be further included.

When the cosmetic composition or external preparation is formulated as a solution or emulsion, a solvent, solubilizing agent, or emulsifying agent may be used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil may be used, in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters , polyethylene glycol or fatty acid esters of sorbitan may be used.

When the cosmetic composition or external preparation is formulated as a suspension, water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used as carrier components.

When the cosmetic composition is formulated as a soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerol, sugar, etc. may be used as carrier components.

The cosmetic composition or skin external preparation is a fatty substance, organic solvent, solubilizer, thickener, gelling agent, softener, antioxidant, suspending agent, stabilizer, foaming agent, fragrance, surfactant, water, ionic or nonionic emulsifier, filler, sequestering agent, chelating agent, preservative, blocking agent, wetting agent, essential oil, dye, pigment, hydrophilic or affinity commonly used in the industry depending on the quality or function of the final product It may additionally contain adjuvants commonly used in the field of cosmetology or dermatology, such as oil-based actives and any other ingredients commonly used in cosmetics.

The liposome cosmetic composition according to the present application may be prepared as a suspension of nano-liposomes by mixing and stirring the aqueous phase and the oil phase. Specifically, the aqueous phase is first mixed, heated to a temperature of 70 to 90 ° C, stirred at 2,500 to 3,500 rpm for 5 to 30 minutes, cooled, mixed with the oil phase, stirred at room temperature at 2,500 to 3,500 rpm for 5 to 30 minutes, then mixed with the water phase and then stirred at 500 to 1,500 rpm for 5 to 30 minutes, then the mixing The liquid may be circulated three or more times at 800 to 1,200 bar using a Microfluidizer (MF) to prepare a nanoliposome suspension.

Hereinafter, the configuration of the present invention and its effects will be described in more detail through specific examples and comparative examples. However, these examples are for explaining the present invention in more detail, and the scope of the present invention is not limited to these examples.

Preparation Example: Preparation of Peptide

Peptides were synthesized using a conventional solid phase peptide synthesis (SPPS) method using 9-fluorenylmethoxycarbonyl (Fmoc) as a protecting group for amino acids. Amino acid residues were extended using N-hydroxybenzotriazole (HOBt) and N,N'-diisopropylcarbodiimide (DIC) as activators [Reference: Wang C. Chan, Perter D. White, 'Fmoc-solid phase peptide synthesis', Oxford].

The synthesized peptide was purified using C18 reverse phase high performance liquid chromatography (HPLC, Waters Associates, USA). ACQUITY UPLC BEH300 C18 (2.1 x 100 mm, 1.7 μM, Waters Co, USA) was used as the column.

Peptides synthesized according to the above method are shown in Table 1 below.

division order note Example YCHFFQASCV SEQ ID NO: 1

Meanwhile, as a comparative example, a known peptide of SEQ ID NO: 2 (YCRFFQASCY) was used.

Experimental Example 1: Skin whitening effect

The whitening effect of peptides was tested using melanin-producing cells.

The reason why the skin darkens is because the melanin-producing cells of the skin make melanin and export it to the epidermis, so if the melanin production of melanin-producing cells and its mechanism are blocked, melanin is not made and skin blackening does not appear. Therefore, the activity of tyrosinase enzyme involved in melanin production and the main steps of melanin synthesis is used as an important measure for whitening.

In this experiment, the skin whitening effect was confirmed by establishing an in vitro assay system using a melanoma cell line and melanin-stimulating hormone to measure the melanin production inhibitory effect and tyrosinase activity inhibitory effect by the peptide.

(1) Cell line and cell culture

The cell lines used in the experiment were melanoma B16F10 cells and human primary melanocyte HEMn- _LP cells (Cascade Biologics, USA). B16F10 cells were prepared in DMEM (D ulbecco's modified Eagle medium) was used (Incubator; Thermo-scientific, USA). HEMn-LP cells were cultured in 99% Medium 254 (Cascade Biologics, USA) mixed with 1% HMGS (Cascade Biologics, USA) at 37°C and 5% CO ₂ conditions (Incubator; Thermo-scientific, USA). B16F10, HEMn-LP cells were sufficiently proliferated in a 100 cm ² flask (Corning, USA), washed the surface of the cultured cells with PBS every 3 days, added 0.25% trypsin-EDTA solution, treated in an incubator for 3 minutes, discarded the trypsin-EDTA solution, and stored at 37 ° C. for 5 minutes to detach the cells. The detached cells were transferred to a new culture vessel in 10 ml of DMEM containing 10% FBS, and subcultured at 37° C. 5% CO ₂ at a split ratio of 1:5.

(2) Whitening effect test through inhibition of tyrosinase activity

B16F10 melanocytes (or HEMn-LP melanocytes) were added to each well of a 6-well plate at 1x10 ⁵ cell/well (Final volume 3ml) and cultured in an incubator at 37°C, 5% CO ₂ for 24 hours. Then, the medium in each well was removed and replaced with new DMEM. In each well, a whitening effect sample was prepared by concentration and pre-treated for 30 minutes.

Subsequently, α-Melanocyte stimulating hormone (α-MSH) was treated with 1 ppm and cultured for 48 hours. Thereafter, the culture medium was removed, 1 ml of PBS was added, and cells were removed by scraping each well with a cell scraper, and transferred to each 1.5 ml tube. Subsequently, the supernatant was removed by centrifugation at 4°C and 1,300 rpm for 3 minutes, and the cell pellet was collected and 200 ml of lysis buffer (100 mM sodium phosphate buffer (pH6.8) containing 1% Triton X-100 and 1 mM PMSF) was added. Cells were lysed by vortexing at 10-minute intervals for 30 minutes, and then centrifuged at 4°C and 1,300 rpm for 30 minutes, and the supernatant was transferred to a new 1.5 ml tube. Total protein was quantified using the BCA protein assay kit (PIERCE, USA), and 40 ml of the same amount of quantified sample was put into each well of a 96 well plate, followed by 2 mg/ml of phosphate buffer (pH 6.8). After reacting at 37 ° C for 30 to 60 minutes, absorbance was measured at 475 nm using an ELISA reader. Based on the negative control group, the inhibition rate (%) of tyrosinase activity was obtained by the following [Equation 4]. The negative control group was treated with DMSO instead of the sample and used as a sample.

Table 2 is a table showing the effect of inhibiting the activity of tyrosinase increased by a-MSH of the peptide by the above method as an embodiment of the present invention.

[Equation 4]

Tyrosinase activity inhibition rate (%) = [(T _m -T _s ) / (T _m -T _c )] × 100

T _c : absorbance of the control group

T _m : Absorbance of α-MSH treated group

T _S : Absorbance of the sample and the group treated with α-MSH

α-MSH addition - + + + + + sample Example 1.5 ppm Example 2.0 ppm Comparative example 1.5 ppm Comparative example 2.0 ppm Tyronease activity % 100% 440% 175% 158% 273% 267% Inhibition rate % 78% 83% 49% 51%

(3) Measurement of melanin production inhibitory effect

B16F10 melanocytes (or HEMn-LP melanocytes) were added to each well of a 6-well plate at 1x10 ⁵ cell/well (Final volume 3ml) and cultured in an incubator at 37°C, 5% CO ₂ for 24 hours. Then, the medium in each well was removed and replaced with new DMEM. In each well, a whitening effect sample was prepared by concentration and pre-treated for 30 minutes.

Thereafter, α-Melanocyte stimulating hormone (α-MSH) was treated with 1 ppm and cultured for 48 hours. Thereafter, the culture medium was removed, 1 ml of PBS was added, and cells were removed by scraping each well with a cell scraper, and transferred to each 1.5 ml tube. Subsequently, the supernatant was removed by centrifugation at 4 ° C and 1,300 rpm for 3 minutes, and the cell pellet was collected and 200 ml of lysis buffer (1% Triton X-100, 1 mM PMSF, 50 mM Tris-HCl (pH7.0), 2 mM EDTA (pH8.0), 150 mM NaCl) was added. After vortexing at 10-minute intervals for 30 minutes, the cells were lysed, centrifuged at 4°C and 1,300 rpm for 30 minutes to remove the supernatant, and the cell pellet was recovered and dried at 60°C for about 3 hours. Then, 150 ml of 2N NaOH with 10% DMSO was added to dissolve the intracellular melanin at 60°C for 1 hour. 100 ml of the supernatant obtained by dissolution was put into each well of a 96 well plate, and absorbance was measured at 405 nm using an ELISA reader. The negative control group was treated with DMSO instead of the sample. The melanin production inhibition rate (%) was obtained by the following [Equation 5].

Table 3 is a chart showing the effect of inhibiting the production of melanin increased by α-MSH of the peptide in the above method as an embodiment of the present invention.

[Equation 5]

Melanin production inhibition rate (%) = [(M _m -M _s )/(M _m -M _c )]×100

M _c : Amount of melanin in the control group

M _m : the amount of melanin in the α-MSH treated group

_MS : Amount of melanin in the sample and the group treated with α-MSH

α-MSH addition - + + + + + sample Example 1.5 ppm Example 2.0 ppm Comparative example 1.5 ppm Comparative example 2.0 ppm Tyronease activity % 100% 230% 135% 121% 167% 158% Inhibition rate % 73% 84% 48% 55%

(4) cAMP production inhibitory effect

The amount of cAMP released into cells was measured using a cAMP ELISA kit (Assay Design, USA). The amount of cAMP generated during cell transfer of skin darkening was measured by ELISA, and the results are shown in FIG. 12 .

As a result of the above experiment, it was confirmed that the peptide had an inhibitory effect on cAMP.

α-MSH addition - + + + + + sample Example 1.5 ppm Example 2.0 ppm Comparative example 1.5 ppm Comparative example 2.0 ppm Tyronease activity % 100% 160% 65% 57% 118% 107 Inhibition rate % 158% 172% 70% 88%

As a result of the experiment as described above, it was confirmed that the embodiment of the present invention is an excellent whitening component compared to the comparative example.

Formulation Examples 1 to 4: Preparation of liposomal cosmetic composition

An embodiment of the present invention was prepared as a cosmetic composition with good percutaneous absorption and a liposome cosmetic composition to implement a stable prescription. After mixing the aqueous phase of the composition shown in Table 5, it was heated to 80 ° C., stirred for 10 minutes, and then cooled (3,000 rpm). After mixing the oil phase of the composition of Table 5 below, it was stirred at room temperature for 10 minutes (3,000 rpm). The water phase and the oil phase were mixed and stirred for 20 minutes (1,500 rpm). The mixture was circulated three times at 1000 bar using a Microfluidizer (MF) to obtain a nanoliposome suspension. After adding the preservatives shown in Table 5, the mixture was stirred for 10 minutes (500 rpm).

Ingredients (% by weight) Prescription Example 1 Prescription example 2 Prescription example 3 Prescription Example 4 Awards Purified water To 100 To 100 To 100 To 100 EDTA-2NA 0.05 0.05 0.05 0.05 oleic acid 0.2 0.3 0.2 0 amino acid histidine 1 lysine 1 0 histidine 1 adenosine One One One One Paid ethanol 10 10 10 10 glycerin 30 30 30 30 1,3-butylene glycol 10 10 10 10 Example Peptide One One One One Phospholipid 3 3 3 3 ceramide One One One One stearic acid 0.3 0.2 0.3 0.5 MCT oil 3 3 3 3 Dibutylhydroxytoluene 0.05 0.05 0.05 0.05 antiseptic SHD-62 (1,2-Hexanediol) One One One One

Experimental Example 2: Particle size analysis and stability test of prescription

In this experiment, the particle size analysis was performed using Helos model equipment from Sympatec, Germany as a particle size analyzer using the light scattering method to confirm the actual size and particle size distribution of the nano-sized multilayer liposomes, which cannot be confirmed with a general optical microscope. Stability test confirmed the change in properties for 1 month at 5 ℃, 25 ℃, 45 ℃, and cycle.

The results of visual observation in [Table 6] were analyzed and verified using a particle size analysis equipment using a light scattering method. Transparency: ◎transparent), ○translucent), △translucent - cloudy), × (milk white)

Prescription Example 1 Prescription example 2 Prescription example 3 Prescription Example 4 Particle size (initial) 110nm 131 nm 459 nm 1424 nm Transparency (initial)
◎ ◎ ◎ ○ particle size (45℃ 1 month) 107 nm 138 nm 560 nm 976 nm transparency
(45℃ months) ◎( ◎ ◎ ○ particle size
(5℃ months) 103 nm 112 nm 340 nm separation transparency
(5℃ 1 month) ◎ ◎ ◎ △ particle size
(Cyc, 1 month) 124 nm 150 nm 810 nm separation transparency
(Cyc, 1 month) ◎( ◎ ◎ △ particle size
(25℃ months) 111 nm 129nm 431 nm 821 nm transparency
(25℃ months) ◎( ◎ ◎ ○

As described above, while formulation examples 1 to 3 had stable particle encapsulation, in formulation example 4, it was confirmed that the properties were cloudy. Accordingly, additional experiments were conducted on Prescription Examples 1 to 3.

Experimental Example 3: Liposome Skin Permeation Test

In order to measure the percutaneous absorption rate of the liposome suspension of the present invention, in vitro skin absorption test guidelines (Ministry of Food and Drug Safety) were followed. The in vitro skin absorption test method confirms that the test substance passes through the skin. It is a method of applying or applying the test substance to the surface of the skin and measuring the amount moved to the solution reservoir inside the skin after a certain period of time. The skin of a human or other species multicellular animal, or artificial skin can be used. In particular, in the case of using artificial skin, it is possible to repeatedly measure the test substance and study the exposure conditions without using laboratory animals. The in vitro skin absorption test can compare skin absorption and permeation according to the composition of the substance, and can be used as a useful model for risk assessment by skin absorption in the human body.

In this experimental example, using an artificial Membrane Strat-M for percutaneous absorption test manufactured by Millipore (USA), the experiment was carried out by attaching it to a Franz-Diffusion Cell and System (LOGAN USA). In the Franz-Diffusion Cell, the donor chamber was kept unsealed with para film under non-occluded conditions.

Each test substance was mixed with a solvent, loaded into the donor chamber, and after a certain period of time, the liquid in the membrane and reservoir was collected and the peptide components were analyzed to confirm the skin permeability of the test substance. In addition, the residual amount remaining on the skin was measured. 100 g of Prescription Examples 1 to 3 was treated on the artificial skin, respectively, and the degree of skin penetration was measured after 2 hours. It is expressed as weight percent of peptides detected based on the total peptide content (1 g).

Prescription Example 1 Prescription example 2 Prescription Example 3 skin 5% 5% 51% membrane 15% 19% 5% Reservoir 35% 31% 3%

In the case of using Formulation Examples 1 and 2 as described above, significant skin absorption was shown through the membrane and reservoir, whereas in Formulation Example 3, it was confirmed that many peptides remained on the skin. Accordingly, Formulation Examples 1 and 2 were designed as suitable formulations.

<110> HAN, DOSOOK <120> Peptide for whitening and cosmetic composition with improved percutaneous absorption comprising the same <130> P22193 <160> 2 <170> KoPatentIn 3.0 <210> 1 <211> 10 <212> PRT <213> artificial sequence <220> <223> peptide <400> 1 Tyr Cys His Phe Phe Gln Ala Ser Cys Val 1 5 10 <210> 2 <211> 10 <212> PRT <213> artificial sequence <220> <223> peptide <400> 2 Tyr Cys His Phe Phe Gln Ala Ser Cys Val 1 5 10

Claims (3)

A cosmetic composition for whitening comprising 0.5 to 5.0% by weight of the peptide of SEQ ID NO: 1 as an active ingredient,
The cosmetic composition, an oil phase containing the peptide, phospholipid, and ceramide; and a formulation in which liposomes are formed through mixing of an aqueous phase containing oleic acid, amino acids, and adenosine;
The amino acid includes histidine or lysine,
The oleic acid is 0.1 to 0.4 parts by weight, the amino acid is 0.8 to 1.2 parts by weight, the adenosine is 0.8 to 1.2 parts by weight, the peptide is 0.8 to 1.2 parts by weight, the phospholipid is 2.5 to 3.5 parts by weight, the ceramide is 0.8 to 1.2 parts by weight, a cosmetic composition for whitening.


delete delete